Karyopharm stock gains on trial data

Karyopharm's stock experienced a notable increase of 10% following the release of mixed Phase 3 trial data. While the data is described as mixed, the market reaction indicates a positive interpretation of the results by investors. The trial likely pertains to one of the company's drug candidates, and the positive stock movement suggests that the positive aspects of the data outweighed any concerns. Further details on the specific trial and its implications are expected.